PMID- 24405794
OWN - NLM
STAT- MEDLINE
DCOM- 20141022
LR  - 20181202
IS  - 1873-3379 (Electronic)
IS  - 0891-4222 (Linking)
VI  - 35
IP  - 3
DP  - 2014 Mar
TI  - The effectiveness of aripiprazole in the management of problem behaviour in 
      people with intellectual disabilities, developmental disabilities and/or autistic 
      spectrum disorder--a systematic review.
PG  - 711-25
LID - S0891-4222(13)00547-7 [pii]
LID - 10.1016/j.ridd.2013.12.004 [doi]
AB  - The management of problem behaviours (PB) in individuals with intellectual 
      disabilities (ID), developmental disabilities (DD) and/or autistic spectrum 
      disorders (ASD) can be challenging. Antipsychotic medications are commonly 
      prescribed where other strategies have failed. A systematic review (SR) was 
      conducted to establish the research evidence for the efficacy of aripiprazole in 
      the management of PB in adults and children with ID, DD and/or ASD. Although 
      included studies supported the efficacy of aripiprazole for this indication, the 
      overall quality of studies was poor. Of the 20 studies included in this 
      systematic review there were only two randomised controlled trials (RCTs) on 
      children with ASD and/or ID/DD, both of which were conducted by the 
      pharmaceutical company that manufactures aripiprazole, and it is not clear 
      whether a number of same participants were included in both RCTs. One of the RCTs 
      was extended into an open label long term follow up, which showed that 
      aripiprazole's efficacy lasted over 52 weeks and the adverse effects were 
      tolerable. Four studies were open label prospective studies, 11 were 
      retrospective case reports which included four single case reports, and two were 
      prospective case series. Most studies reported adverse effects from aripiprazole 
      in the form of weight gain, increased appetite, sedation, tiredness, drooling and 
      tremor. However, aripiprazole improved serum prolactin level in some participants 
      and overall did not show any adverse effect on QTc interval. There is a need for 
      more carefully designed RCTs into the use of aripiprazole in the management of PB 
      in people with ID/DD and/or ASD, which should be carried out independent of 
      pharmaceutical companies.
CI  - Copyright (c) 2013 Elsevier Ltd. All rights reserved.
FAU - Deb, Shoumitro
AU  - Deb S
AD  - Imperial College, London, UK.
FAU - Farmah, Baldeep K
AU  - Farmah BK
AD  - School of Psychiatry, West Midlands Deanery, Birmingham, UK.
FAU - Arshad, Ebrahim
AU  - Arshad E
AD  - University of Birmingham, UK.
FAU - Deb, Tanya
AU  - Deb T
AD  - Imperial College, London, UK.
FAU - Roy, Meera
AU  - Roy M
AD  - Birmingham Community Healthcare NHS Trust, UK. Electronic address: 
      meera.roy@nhs.net.
FAU - Unwin, Gemma L
AU  - Unwin GL
AD  - School of Psychology, University of Birmingham, UK.
LA  - eng
PT  - Journal Article
PT  - Review
PT  - Systematic Review
DEP - 20140107
PL  - United States
TA  - Res Dev Disabil
JT  - Research in developmental disabilities
JID - 8709782
RN  - 0 (Antipsychotic Agents)
RN  - 0 (Piperazines)
RN  - 0 (Quinolones)
RN  - 82VFR53I78 (Aripiprazole)
SB  - IM
MH  - Aggression
MH  - Antipsychotic Agents/*therapeutic use
MH  - Aripiprazole
MH  - Child Development Disorders, Pervasive/complications/*drug therapy
MH  - Developmental Disabilities/complications/*drug therapy
MH  - Humans
MH  - Intellectual Disability/complications/*drug therapy
MH  - Mental Disorders/complications/drug therapy
MH  - Piperazines/*therapeutic use
MH  - Quinolones/*therapeutic use
MH  - Self-Injurious Behavior/complications/*drug therapy
MH  - Treatment Outcome
OTO - NOTNLM
OT  - ASD
OT  - Aggression
OT  - Aripiprazole
OT  - Developmental disabilities
OT  - Intellectual disabilities
OT  - Problem behaviour
OT  - Self-injurious behaviour
EDAT- 2014/01/11 06:00
MHDA- 2014/10/23 06:00
CRDT- 2014/01/11 06:00
PHST- 2013/10/23 00:00 [received]
PHST- 2013/12/10 00:00 [accepted]
PHST- 2014/01/11 06:00 [entrez]
PHST- 2014/01/11 06:00 [pubmed]
PHST- 2014/10/23 06:00 [medline]
AID - S0891-4222(13)00547-7 [pii]
AID - 10.1016/j.ridd.2013.12.004 [doi]
PST - ppublish
SO  - Res Dev Disabil. 2014 Mar;35(3):711-25. doi: 10.1016/j.ridd.2013.12.004. Epub 
      2014 Jan 7.